SPX3,831.39+6.06 0.16%
DIA309.71-1.14 -0.37%
IXIC11,322.24+194.39 1.75%

AbbVie Says Combination Leukemia Therapy Sustained Progression-Free Survival in Phase 3 Trial

MT Newswires · 06/09/2022 23:43

Please log in to view news